Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 14:56:22 UTC 2023
by
admin
on
Sat Dec 16 14:56:22 UTC 2023
|
| Protein Type | RECEPTOR |
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
71TF1I38OY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
O95977
Created by
admin on Sat Dec 16 14:56:23 UTC 2023 , Edited by admin on Sat Dec 16 14:56:23 UTC 2023
|
PRIMARY | |||
|
1695594-32-1
Created by
admin on Sat Dec 16 14:56:23 UTC 2023 , Edited by admin on Sat Dec 16 14:56:23 UTC 2023
|
PRIMARY | |||
|
71TF1I38OY
Created by
admin on Sat Dec 16 14:56:23 UTC 2023 , Edited by admin on Sat Dec 16 14:56:23 UTC 2023
|
PRIMARY |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_2 |
| N | 1_30 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
AGONIST -> TARGET |
Phase2 clinical trial results of siponimod and ceralifimod suggest that S1P3 and S1P4 targeting are not needed for therapeutic efficacy.
|
||
|
|
PARTIAL AGONIST->TARGET |
Relative efficacY of 63% of S1P1 activity
EC50
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT | CHEMICAL |
|